Effects of Rosmarinic Acid on Acetaminophen-induced Hepatotoxicity in Male Wistar Rats
Overview
Authors
Affiliations
Context: Drug-induced liver injury is a significant worldwide clinical problem. Rosmarinic acid (RA), a natural phenol, has antioxidant effects.
Objective: The effects of RA against acetaminophen (N-acetyl-p-amino-phenol (APAP))-induced oxidative damage and hepatotoxicity in rats were investigated.
Materials And Methods: Male Wistar rats were pretreated with RA (10, 50 and 100 mg/kg, i.g.) for one week. On day 7, rats received APAP (500 mg/kg, i.p.). Then aspartate aminotransferase (AST), alanine aminotransferase (ALT), albumin, total protein, malondialdehyde (MDA), glutathione (GSH), total antioxidant capacity (TAC), glutathione S-transferase (GST), cytochrome CYP450 and histopathological changes were determined.
Results: APAP-induced oxidative stress in liver by a significant increase in the level of MDA (7.6 ± 0.21 nmol/mg) as well as a decrease in the contents of TAC (1.75 ± 0.14 μmol/g), GSH (1.9 ± 0.22 μmol/g) and GST) 3.2 ± 0.28 U/mg). RA treatment decreased MDA (4.32 ± 0.35 nmol/mg) but increased the contents of TAC (3.51 ± 0.34 μmol/g), GSH (3.42 ± 0.16 μmol/g) and GST (5.71 ± 0.71 μmol/g) in APAP group. RA 100 mg/kg decreased ALT (91.5 ± 1.5 U/L), AST (169 ± 8.8 U/L) and CYP450 (3 ± 0.2 nmol/min/mg) in APAP group. Histologically RA attenuated hepatic damage by decreasing necrosis, inflammation, and haemorrhage in liver sections of APAP group.
Discussion And Conclusions: This is the first report that oral administration of RA dose-dependently elicited significant hepatoprotective effects in rats through inhibition of hepatic CYP2E1 activity and lipid peroxidation. RA-protected hepatic GSH and GST reserves and total tissue antioxidant capacity.
Anti-Tumor Effects and Toxicity Reduction Mechanisms of : A Comprehensive Review.
Ning N, Nan Y, Chen G, Huang S, Lu D, Yang Y Molecules. 2024; 29(8).
PMID: 38675663 PMC: 11052495. DOI: 10.3390/molecules29081843.
Rasouli H, Razavi B, Rahbardar M, Sadeghian H, Tabatabaee Yazdi S, Hosseinzadeh H Naunyn Schmiedebergs Arch Pharmacol. 2024; 397(8):6001-6015.
PMID: 38381146 DOI: 10.1007/s00210-024-03000-2.
Elsafty M, Abdeen A, Aboubakr M Naunyn Schmiedebergs Arch Pharmacol. 2023; 397(1):317-328.
PMID: 37436496 PMC: 10771367. DOI: 10.1007/s00210-023-02609-z.
Balachander G, Subramanian S, Ilango K RSC Adv. 2022; 8(47):26656-26663.
PMID: 35547559 PMC: 9087887. DOI: 10.1039/c8ra02849d.
Khelfallah A, Aouay B, Kebieche M, Fetoui H Iran J Pharm Res. 2021; 20(3):577-591.
PMID: 34904010 PMC: 8653642. DOI: 10.22037/ijpr.2021.114487.14878.